🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

CareCloud, Inc. CCLD PHARMA

Healthcare · Health Information Services · United States
https://www.carecloud.com
Company Profile ↓
$2.17
-14.90% 1Y
Mkt Cap$92.21M
P/E31.00
P/B5.16
52W High$3.84
52W Low$2.08
Book Value$0.41
EPS (TTM)$0.07

Company Overview

CareCloud, Inc., a healthcare information technology company, provides technology-enabled business solutions, Software-as-a-Service offerings, and related business services to healthcare providers and hospitals primarily in the United States. It operates through Healthcare IT and Medical Practice Management segments. The company's proprietary software and business services includes technology-enabled business solutions; cloud-based software; digital health services; healthcare IT professional services and staffing; MAP App; and medical practice management services. It also offers revenue cycle management services, healthcare claims clearinghouse, and medical coding and credentialing services; electronic health records, practice management software and related capabilities, patient experience management solutions, business intelligence and healthcare analytics platforms, and customized applications, interfaces, and various other technology solutions, as well as artificial intelligence, such as CareCloud cirrusAI, AI-powered clinical decision support, AI-powered virtual support assistant, AI-driven appeals, Stratus AI Desk Agent, and CareCloud cirrusAI. In addition, the company provides chronic care management, remote patient monitoring, and telemedicine solutions; professional services; managed services; workforce augmentation; on-demand staffing; and strategic advisory services. Further, it offers medical practice management services to medical practices comprising appropriate facilities, equipment, supplies, support services, nurses, and administrative support staff, as well as management, bill-paying, and financial advisory services. It serves physicians, nurses, nurse practitioners, therapists, physician assistants, and other clinicians that render bills for their services. The company was formerly known as MTBC, Inc. and changed its name to CareCloud, Inc. in March 2021. CareCloud, Inc. was founded in 1999 and is headquartered in Somerset, New Jersey.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 21.8%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 17.9%.

Steady Revenue Expansion

Revenue has grown at a 22.6% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $120.50M (+8.7% YoY); net profit $10.80M.
  • Trailing 12 Months Year-on-year growth — revenue +16.4%, earnings -88.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 22.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:22.58%
1 Year:16.40%

Compounded Profit Growth

5 Years:-
1 Year:-88.30%

Stock Price Performance

1 Year:-14.90%
6 Months:-20.51%
3 Months:-8.44%
1 Month:-17.49%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 5% of range
$2.08 $3.84
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)38.56 · Neutral
Price Performance
1M-17.49%
3M-8.44%
6M-20.51%
1Y-14.90%
Valuation vs Sector

P/E of 31.00 is above the sector median of 24.83 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 21.8%.
  • Compounding revenue at 22.6% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 43.5% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
31.00
Industry PE
24.83
Forward P/E
5.09
PEG Ratio
0.31
Book Value
$0.41
Price to Book
5.16
P/S
0.70
EV/EBITDA
8.79
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
22.58%
Profit 5Y
-
Revenue (YoY)
16.40%
Earnings (YoY)
-88.30%

Profitability & Returns

ROCE
17.95%
ROE
21.75%
ROA
6.82%
Profit Margin
6.21%
Op Margin
5.73%
Gross Margin
46.50%
EPS (Latest Qtr)
$0.00
EPS (TTM)
$0.07

Balance Sheet & Liquidity

Debt/Equity
3.10
Quick Ratio
0.92
Current Ratio
1.02
Debt
$54.01M
Total Assets
$93.85M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
15.25%
Chg in Prom Hold
0.07%
FII / Inst Holding
23.16%
Chg in FII Hold
0.20%

Financial Snapshot

Enterprise Value
$92.21M
Total Revenue (TTM)
$128.64M
EBITDA
$15.12M
Free Cash Flow
$22.63M
Operating Cash Flow
$26.72M
Shares Outstanding
42.49M
Gross Margin
46.50%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 CCLD CareCloud, Inc. PHARMA 2.17 31.00 $92.21M 0.00% 17.95% 21.75% 22.58% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2013Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue ------------7.78M7.51M8.31M8.68M17.04M15.08M16.75M16.85M21.87M19.58M31.64M29.77M34.06M38.30M35.34M37.23M33.72M30.00M29.36M29.28M25.96M28.09M28.55M27.63M27.38M31.07M31.27M31.88M
Operating Income -157.99K-216.69K-321.93K-388.60K-2.40M-1.17M-1.50M-1.28M-1.80M-1.07M-1.27M-2.41M-1.38M-274.96K39.12K72.45K-1.78M-238.00K-1.23M669.42K-2.84M-4.61M-1.24M-1.68M-106.00K1.43M1.22M2.75M1.69M-223.00K-1.29M-1.97M129.00K2.27M3.27M2.02M3.00M3.21M1.00M1.86M
Net Income -87.46K-138.02K-383.67K-289.40K-2.84M-1.17M-1.49M-1.23M-1.98M-1.29M-1.49M-2.71M-1.69M-980.12K75.04K195.28K-1.83M-295.69K-770.97K-137.54K-2.50M-4.79M-1.67M-1.96M-227.00K1.50M1.14M2.74M1.06M-401.00K-1.83M-2.75M-241.00K1.67M3.12M1.95M2.90M3.06M922.00K1.12M
Diluted EPS -0.02-0.03-0.08-0.06-0.34-0.12-0.15-0.13--------------------0.07-0.18-0.28-0.37-0.42-0.10-0.14-0.04-0.040.040.04-0.010.00
R&D Expense 98.97K94.54K116.43K126.11K154.06K164.93K165.25K159.14K190.79K209.40K174.88K280.85K313.40K249.04K255.88K248.92K263.72K254.66K218.41K175.76K2.33M2.15M2.37M2.03M1.81M488.00K985.00K1.10M1.17M1.08M1.19M1.26M913.00K1.05M800.00K1.24M1.02M1.58M2.42M2.19M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 10.47M18.30M23.08M24.49M31.81M50.55M64.44M105.12M139.60M138.83M117.06M110.84M120.50M
Operating Income -127.52K-4.04M-4.46M-7.90M-4.52M-2.54M67.00K-8.27M3.53M6.61M-47.12M9.12M11.34M
Net Income -178.00K-4.51M-4.69M-8.80M-5.57M-2.14M-872.00K-8.81M2.84M5.43M-48.67M7.85M10.80M
Diluted EPS -0.03-0.64--------0.67-4.11-0.280.10
R&D Expense 386.11K531.68K659.18K902.19K1.08M1.03M871.00K9.31M4.41M4.40M4.74M3.78M6.38M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Jan 2018Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -5.77M23.11M26.68M28.32M25.53M-47.62M56.40M138.00M140.85M136.17M77.83M71.61M87.60M
Total Equity 406.08K118.50K14.32M14.89M7.07M20.25M21.69M38.87M42.84M101.25M97.93M101.69M41.72M49.77M59.51M
Cash & Equivalents 268.32K497.94K1.05M8.04M3.48M4.36M-14.47M19.99M20.93M9.34M12.30M---
Long Term Debt --04.84M4.03M----------
Total Liabilities -5.65M8.79M11.78M21.26M5.28M-8.75M13.56M36.75M42.92M34.48M36.11M21.84M28.09M
Current Liabilities -3.41M8.14M5.76M15.86M4.32M-8.16M11.18M29.02M29.56M22.40M23.30M19.58M24.42M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow --1.88M-889.34K281.64K6.81M7.62M-892.00K-21.15M15.46M20.64M28.56M
Investing Cash Flow --602.42K-3.83M-902.21K-13.63M-4.16M-31.47M--11.77M-11.61M-7.41M-24.54M
Financing Cash Flow -9.50M148.81K1.84M17.66M1.42M33.42M--7.65M-13.29M-11.26M-5.61M
Capital Expenditure ------2.02M-2.59M--11.77M-11.61M-7.41M-8.03M
Free Cash Flow -----5.60M-3.48M-9.38M3.85M13.24M20.53M
Net Change in Cash --------1.73M-9.44M1.98M-1.58M
Share Buybacks 0122.03K546.14K---------

Ratios (Annual)

Figures in %.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------
Operating Margin % -1.2%-22.1%-19.3%-32.3%-14.2%-5.0%0.1%-7.9%2.5%4.8%-40.2%8.2%9.4%
Net Margin % -1.7%-24.6%-20.3%-35.9%-17.5%-4.2%-1.4%-8.4%2.0%3.9%-41.6%7.1%9.0%
ROE % -150.2%-31.5%-31.5%-124.5%-27.5%-5.5%-2.0%-8.7%2.9%5.3%-116.7%15.8%18.1%
ROCE % -5.4%-27.0%-21.3%-63.4%-21.3%-6.4%0.1%-7.6%3.2%5.8%-86.4%17.5%18.0%

Shareholding Pattern

Insiders
15.25%
Institutions
23.16%
Public Float
27.33%

Top Institutional Holders

#Holder% HeldSharesValue
1 Vanguard Capital Management LLC 3.96% 1.68M $3.65M
2 Hillsdale Investment Management Inc. 2.17% 923.41K $2.00M
3 Dimensional Fund Advisors LP 1.36% 575.97K $1.25M
4 Two Sigma Investments, LP 1.36% 579.83K $1.26M
5 American Century Companies Inc 1.20% 509.69K $1.11M
6 Ameriprise Financial, Inc. 1.04% 441.65K $958.38K
7 Geode Capital Management, LLC 0.99% 421.58K $914.83K
8 Bridgeway Capital Management, LLC 0.96% 409.26K $888.09K
9 Wells Fargo & Company 0.91% 385.00K $835.45K
10 Globeflex Capital L P 0.79% 335.15K $727.27K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CCLD

Google News Wed, 19 Aug 2026

CCLD | CareCloud, Inc. Common Stock Financials - Revenue Breakdown - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9zVXoxa0hIeFNYMFBTXzhGSEtmSXFLOTFDdWRXRUd4WDdkTDZ5LWw5V3lBak13S3dPM25QdDQxM0NzeVpWTnBjM2hPR2h3VVZMMzlaaDd3NjU2REZHR2o3RENfUTBUeDRDd3R3eDZSX0ZUak1XblNF?oc=5" target="_blank">CCLD | …

Google News Wed, 15 Apr 2026

Is CareCloud (CCLD) Stock Undervalued Right Now? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPRnE2VWtMVlF5di1FNjdZMDItVGxWR1Q2TUV5UUNKeE1jWElKbHNvaFZCSlotM0NZc3NDZnREQW5USkdEV0xwMG5obHZqaGlyVDVueE1fU3RBT2F5TGhPZl9fOUMxUEV5NXZIRElOWXItcEdEbTI1QWktTEdEVlpzbVlIOE91UGVOUnpfMH…

Google News ue, 26 May 2026

CCLD - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9uMTR1VWtfN1hDRW85YmtPcnpNOEVmRGJSWFA1aG5UeVZaOExBck1COWxVLVRUWDZqTDNsa0JjVWFnNFh5dEE?oc=5" target="_blank">CCLD</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

Google News Fri, 31 Jul 2026

CareCloud (CCLD) director reports 25,000 RSU grant and 6,250-share vesting - Stock Titan

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNM21qakhhdTlmV1RJOU0wSTBKVFVJUGJpcHl0bmN6MnVCOVBDamZ2TzZlYWFIcmFUN0llcjdJZW9JenA3OWg3d1M0SGdEank1U1VnT3lMQzU5TGFBTXFIa2t6T2xHRWxDMzczVzFmSXlNMWJ0NWlIRU1IMFVudzg5MWRBenB3SVJuNThoZm…

Google News hu, 19 Mar 2026

CareCloud, Inc. Common Stock (CCLD) Stock Price Today: $2.26 - Gotrade

<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTE16Tk9DNERJa0o3T0YxTHZodGN5dVlacl81Q0Rtd2I1Z3dIMll5X1o1VExkS1picnRSTldBS195UUE0NV9TUVU4U0poSVFIMzhjNlZ2TGJHVQ?oc=5" target="_blank">CareCloud, Inc. Common Stock (CCLD) Stock Price T…

Google News Mon, 30 Mar 2026

Should Value Investors Buy CareCloud (CCLD) Stock? - qz.com

<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE9YUVZjSTZvcW5PRTFPVkhXZm1VaGZjNXZiM3lBbEZSY2w0Y1IzSDhOV190V3Mycm4xM0ZpQ2VTU0QwV1VoYUZHSTZFdU53aW9xWVRVWUJzQmJneUxFa0plOFNwbTQ2VFpocVpXVzdlSQ?oc=5" target="_blank">Should Value Inve…

CCLD — Frequently Asked Questions

What is the current share price of CareCloud, Inc. (CCLD)?

As of 2026-09-19 21:16 PDT, CareCloud, Inc. (CCLD) trades at $2.17 on NasdaqGM. Its 52-week range is $2.08 to $3.84.

What is the market capitalisation of CCLD?

CareCloud, Inc. (CCLD) has a market capitalisation of $92.21M on NasdaqGM.

What is the P/E ratio of CCLD?

CCLD trades at a trailing price-to-earnings (P/E) ratio of 31.00. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.16.

What is the return on equity (ROE) of CCLD?

CCLD has a return on equity (ROE) of 21.75%. Its return on capital employed (ROCE) is 17.95%.

Is CCLD a good stock to buy?

This page provides a data-driven analysis of CareCloud, Inc. (CCLD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space